IARC

Berry Oncology launches HIFI Pan-Cancer Screening, a multi-cancer early screening product for detecting six high-risk cancers at one time

Retrieved on: 
Jeudi, juin 23, 2022
Qiming Venture Partners, Solution, Industry, Public health, Central committee, Overalls, Environment, Technology, Compliance, Hospital, Survival rate, WGS, Research, CEO, Survival, International Agency for Research on Cancer, Stomach, Recurrence, Liver cancer, HIFI, Pancreatic cancer, DNA, Nucleic acid thermodynamics, Colorectal cancer, Ecosystem, NGS, Quality of life, National Cancer Center, Esophageal cancer, Whole genome sequencing, University, State Council, Lung cancer, Patient, Organic, Communist party, Medicine, IARC, Diagnosis, Genetic testing, Awareness, Central China, Chinese Academy of Sciences, Chinese Academy of Medical Sciences COVID-19 vaccine, Goal, Mobile phone, Medical imaging, Cancer

HIFI Pan-Cancer Screening is the first early screening product for multiple cancer types using whole genome sequencing (WGS) of cell-free DNA (cfDNA) worldwide.

Key Points: 
  • HIFI Pan-Cancer Screening is the first early screening product for multiple cancer types using whole genome sequencing (WGS) of cell-free DNA (cfDNA) worldwide.
  • The self-iterative HIFI technology platform can reduce the costs of product development and testing services, and thus making early screening for multiple cancers more affordable.
  • The launch of the multi-cancer early screening product will further reinforce Berry Oncology's leadership in the early screening sector."
  • Moving forward, Berry Oncology will continue to optimize its technology system and iterate early screening products to deliver more advanced early cancer screening solutions in accordance with the actual market demand and environment.

Nucleix Expands EU Label Indication of Bladder EpiCheck® to Include the Detection of Primary Bladder Cancer and Detection of Primary and Recurrent Upper Tract Urinary Cancer

Retrieved on: 
Mercredi, juin 22, 2022
Biotechnology, Medical Devices, Health, Genetics, Oncology, Population, Union, Disease, Lung, Neoplasm, Malignancy, PCR, Bladder cancer, Life, Liquid biopsy, Technology, Cystoscopy, List of American Medical Association journals, DNA, Urinary bladder, Pathology, Squamous cell carcinoma, Ureter, Kidney, Triage, Recurrence, Medical Affairs Bureau, International Agency for Research on Cancer, NGS, Systematic review, Upper Tract, West Virginia, Organic, Erratum, Patient, IARC, Diagnosis, Blood, DNA methylation, The Journal of Urology, JAMA, Jurgis Matulaitis-Matulevičius, Research, Company, EMEA, UTUC, NPV, Sale, Medical imaging, Medical device, MD, Hematuria, Cancer, EU, Urine, Urology

With this expanded label indication and high specificity of Bladder EpiCheck in this population, were able to offer a cost-effective, non-invasive approach to triage hematuria patients and help identify bladder cancer early.

Key Points: 
  • With this expanded label indication and high specificity of Bladder EpiCheck in this population, were able to offer a cost-effective, non-invasive approach to triage hematuria patients and help identify bladder cancer early.
  • Bladder EpiCheck provides patients and clinicians with a simple, objective urine test to detect primary and recurrent bladder and upper urinary tract cancers.
  • Bladder EpiCheck is intended for use as a non-invasive method for detection of urinary tract cancers in conjunction with standard methods.
  • The Company is building an EpiCheck franchise, beginning with the Bladder EpiCheck testing kit, marketed in Europe for the detection of primary and recurrent bladder cancer and Upper Tract Urinary Cancer.

Global Genome Editing Market Report to 2027 - Featuring Thermo Fisher Scientific, Horizon Discovery and GenScript Among Others - ResearchAndMarkets.com

Retrieved on: 
Mardi, juin 21, 2022
Biotechnology, Genetics, Health, Heart, Agriculture, COVID-19, Government, Research, Lists of diseases, Food, International Agency for Research on Cancer, Brain, CRISPR, Growth, DNA, Gene editing, Investment, Farmer, Genome, Organic, Patient, United Kingdom, IARC, Genetic disorder, NIH, Pharmaceutical industry, Cancer

The "Genome Editing Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genome Editing Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Furthermore, the support of various governments worldwide for the use of genome editing to improve crop yields is another prominent factor expected to drive the genome editing market.
  • Moreover, the growing cases of cancer and other genetic disorders are surging the need for effective treatment and consequently leading to the market growth of genome editing.
  • This led to a positive impact on the genome editing market and increased the expected growth rates of the genome editing market in 2020 and 2021.

High Potency Active Pharmaceutical Ingredient (HPAPI) Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Jeudi, juin 16, 2022
Biotechnology, Pharmaceutical, Health, Erectile dysfunction, Bristol Myers Squibb, Investor, Novartis, Safety, World, Environment, Death, Research, Efficiency, Glaucoma, Growth, CVD, Degenerative disease, API, Eye, Incidence, Organic, IARC, Optic nerve, Diabetes, Fine chemical, Pharmaceutical industry, Sanofi, Cancer

The "HP (High Potency) APIs Global Market Report 2022: By Type, By Synthesis, By Therapeutic" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HP (High Potency) APIs Global Market Report 2022: By Type, By Synthesis, By Therapeutic" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the high potency APIs (HPAPI) market are Eli Lily and Company; Novartis AG; Bristol-Myers Squibb Company; Roche Diagnostics Ltd; Sanofi.
  • The high potency APIs (HPAPI) market consists of sales of high potency active pharmaceutical ingredients and related services.
  • Therefore, large investment requirement acts as a major challenge for the growth of the high potency APIs market.

Global Precision Medicine Market to 2031 - Featuring Qiagen, Novartis and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Jeudi, juin 9, 2022
Health, Pharmaceutical, University, Precision medicine, Research, Cell, DNA repair, Lists of diseases, Degenerative disease, Organic, Disease, Environment, Organization, Neoplasm, Pancreatic cancer, Physician, Growth, IARC, Patient, Hospital, Pharmacotherapy, DNA, International Agency for Research on Cancer, University of Glasgow, Prevalence, Clinical trial, Drug discovery, Asia-Pacific, Health, Genomics, Death, Pharmaceutical industry, Cancer

The main technologies involved in precision medicine are bioinformatics, big data analytics, drug discovery, gene sequencing, companion diagnostics, and others.

Key Points: 
  • The main technologies involved in precision medicine are bioinformatics, big data analytics, drug discovery, gene sequencing, companion diagnostics, and others.
  • North America was the largest region in the precision medicine market in 2021.
  • The rising prevalence of cancer is projected to fuel the growth of the precision medicine market in the coming years.
  • The development of novel precision medicine for pancreatic cancer is shaping the precision medicine market.

IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil

Retrieved on: 
Jeudi, juin 9, 2022
Kidney, Freezing, Brazilian Health Regulatory Agency, Company, Lung, ANVISA, Food, Annual report, Breast cancer, Liver, Cancer, WHO, World Health Organization, TASE, Breast, Prostate, Risk, IARC, Patient, Private Securities Litigation Reform Act, Technology, Genta (company), CE marking, NASDAQ, SEC, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, World, Medical device, Medical imaging

KTRFIOS has submitted this regulatory filing as part of an agreement signed with IceCure which includes KTRFIOS' guarantee of at least $6.6 million in total sales for five years following such regulatory approval and a down payment of $344,000 for 50% of the initial order.

Key Points: 
  • KTRFIOS has submitted this regulatory filing as part of an agreement signed with IceCure which includes KTRFIOS' guarantee of at least $6.6 million in total sales for five years following such regulatory approval and a down payment of $344,000 for 50% of the initial order.
  • Therefore, IceCure believes there is a clear need for minimally-invasive cancer treatments, such as ProSense, in the Brazilian market.
  • This regulatory application reflects the broad number of indications for which our ProSense system can provide a highly effective, minimally invasive, and safe method of treatment for cancer patients," stated IceCure CEO Eyal Shamir.
  • "Regulatory approvals in Brazil would add to our global regulatory landscape which now encompasses various indications across 14 countries including the U.S. and Europe."

Global Lymphedema Treatment Market (2022 to 2030) - Share, Size, Trends, Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Jeudi, juin 2, 2022
Oncology, Medical Devices, Health, Surgery, Radiology, Pharmaceutical, Lymphedema, Conditional sentence, Lymph, Organic, Secondary lymphedema, Disease, Government, Centers for Disease Control and Prevention, CDC, Center, Growth, IARC, Patient, Risk, International Agency for Research on Cancer, Research, Prevalence, Industry, Population, Drug discovery, Forecasting, Ageing, Pharmaceutical industry, Cancer

The increasing number of individuals being affected by Lymphedema is anticipated to drive the growth of the Lymphedema cure industry.

Key Points: 
  • The increasing number of individuals being affected by Lymphedema is anticipated to drive the growth of the Lymphedema cure industry.
  • Furthermore, the increasing healthcare expenditure coupled with the growing innovation across the healthcare sector is further projected to drive the industry growth.
  • In addition, the launch of new medical devices by pharmaceutical companies is also fueling industry growth across the globe.
  • Based on the type, the secondary Lymphedema segment is dominating the global industry and is anticipated to lead the industry over the forecasting period.

Global Next-Generation Antibody Market Forecast to 2028: Proliferation of Biotechnology Industry in Developing Regions - ResearchAndMarkets.com

Retrieved on: 
Mercredi, avril 20, 2022
Health, Biotechnology, Technology, Monoclonal antibody, COVID-19, WHO, International Agency for Research on Cancer, Azerbaijan and Organization for Economic Co-operation, CAGR, Autoimmunity, FC, Growth, IARC, Geography, OECD, Organic, Organization, Economy, Prevalence, World Health Organization, Therapy, Research, Vaccine, Cancer, Development

The "Next-Generation Antibody Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Area and Technology" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Antibody Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Area and Technology" report has been added to ResearchAndMarkets.com's offering.
  • Factors such as the increasing prevalence of cancer and growing demand for next-generation antibody therapeutics are boosting the market growth.
  • However, complications associated with the manufacturing and approvals hamper the growth of the next-generation antibody market.
  • Based on technology, the next-generation antibody market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products.

EdiGene Enters Research Collaboration With Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer

Retrieved on: 
Mercredi, avril 13, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, CEO, Colorectal cancer, World Cancer Research Fund International, Research, WCRF, RNA, Department, Patient, Biomarker, Gene editing, World, Lists of diseases, World Cancer Research Fund UK, IARC, Stem cell, Gene, Large intestine, Mutation, Lung cancer, Precision medicine, Pharmaceutical industry, Medical imaging, Cancer

The research result is expected to enable the development of precision medicine for patients pre-screened by specific mutation patterns.

Key Points: 
  • The research result is expected to enable the development of precision medicine for patients pre-screened by specific mutation patterns.
  • By leveraging EdiGenes systematic research on related genes responding to specific targeted therapy for advanced colorectal cancer, and our extensive research and practical experience, we will support the development of innovative therapies for patients with advanced colorectal cancer.
  • EdiGenes high-throughput genome-editing screening platform uses high-throughput screening and bioinformatics analysis to develop new biomarkers and potential targeted therapies.
  • This collaboration will explore biomarkers that are applicable to patients in China with advanced colorectal cancer to identify targeted therapies best suited to treat their particular cancer.

Global PET-CT Scanner Device Market to 2027 - Size, Share & Industry Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Lundi, avril 11, 2022
Radiology, Health, Adoption, CAGR, Lung, Radiopharmaceutical, Diagnosis, Colorectal cancer, Organic, PET-CT, Artifact, Research, Motion, CT, Application, PET/CT, Neurological disorder, Alzheimer's disease, Neoplasm, Prevalence, International Agency for Research on Cancer, Lung cancer, Service provider, Global, Industry, Technology, Anatomy, Correction, Degenerative disease, Maintenance, PET, Breast cancer, Protein, Patient, Disease, IARC, Radiation, Medical imaging, Cancer

The "Global PET-CT Scanner Device Market Size, Share & Industry Trends Analysis Report By Slice Count, By Isotope/Detector Type, By Service Provider, By Type, By Application, By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PET-CT Scanner Device Market Size, Share & Industry Trends Analysis Report By Slice Count, By Isotope/Detector Type, By Service Provider, By Type, By Application, By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global PET-CT Scanner Device Market size is expected to reach $2.6 billion by 2027, rising at a market growth of 5.5% CAGR during the forecast period.
  • In addition, by detecting changes at the cellular level, it can detect the early onset of disease before other imaging tests.
  • In addition, major global and domestic players have entered this profitable industry, offering refurbished equipment to healthcare facilities around the world at inexpensive pricing.